Sutro Biopharma, Inc. (STRO): Price and Financial Metrics


Sutro Biopharma, Inc. (STRO)

Today's Latest Price: $12.86 USD

0.35 (-2.65%)

Updated Oct 30 4:00pm

Add STRO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

STRO Stock Summary

  • STRO's went public 2.1 years ago, making it older than only 4.29% of listed US stocks we're tracking.
  • STRO's price/sales ratio is 11.48; that's higher than the P/S ratio of 88.55% of US stocks.
  • With a year-over-year growth in debt of 89.61%, Sutro Biopharma Inc's debt growth rate surpasses 86.58% of about US stocks.
  • Stocks that are quantitatively similar to STRO, based on their financial statements, market capitalization, and price volatility, are CLSN, ALBO, RMBS, BBIO, and SURF.
  • Visit STRO's SEC page to see the company's official filings. To visit the company's web site, go to www.sutrobio.com.

STRO Stock Price Chart Interactive Chart >

Price chart for STRO

STRO Price/Volume Stats

Current price $12.86 52-week high $13.91
Prev. close $13.21 52-week low $6.00
Day low $12.30 Volume 112,100
Day high $13.44 Avg. volume 181,164
50-day MA $11.20 Dividend yield N/A
200-day MA $9.96 Market Cap 461.40M

Sutro Biopharma, Inc. (STRO) Company Bio


Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company’s product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was founded in 2003 and is based in South San Francisco, California.


STRO Latest News Stream


Event/Time News Detail
Loading, please wait...

STRO Latest Social Stream


Loading social stream, please wait...

View Full STRO Social Stream

Latest STRO News From Around the Web

Below are the latest news stories about Sutro Biopharma Inc that investors may wish to consider to help them evaluate STRO as an investment opportunity.

Sutro Bio to discuss STRO-002 interim data on in ovarian cancer on Sept. 9

Sutro Biopharma (STRO) will host a conference call on Sept. 9, at 5:30 p.m. EDT to discuss updated data from ongoing Phase I dose escalation study of anti-Folate Receptor alpha (FRα) antibody-drug conjugate ((ADC)), STRO-002, in ovarian and endometrial cancer, with a data cut-off date of Aug. 31, 2020.Additionally, the company...

Seeking Alpha | September 3, 2020

Were Hedge Funds Right About Souring On Sutro Biopharma, Inc. (STRO)?

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. […]

Yahoo | July 1, 2020

Sutro Biopharma Presents New Preclinical Data at 2020 AACR Virtual Annual Meeting II Suggesting Synergy between its STRO-002 Antibody-Drug Conjugate and Immune Checkpoint Inhibitors Resulting in Tumor Regression and Adaptive Anti-Tumor Immunity

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced the presentation of new preclinical data for its folate receptor alpha (FolRα) targeting antibody-drug conjugate, STRO-002, at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II from June 22-24, 2020. The data, being presented by Sutro's Chief Scientific Officer, Trevor Hallam, Ph.D., demonstrates STRO-002's immune-modulating properties and potentiation by PD-L1 blockade.

Yahoo | June 22, 2020

Scott+Scott Attorneys at Law LLP Announces Investigation into Sutro Biopharma, Inc. (STRO)

Scott+Scott Attorneys at Law LLP announces investigation into Sutro Biopharma, Inc. (STRO) and encourages shareholders with losses to contact the Firm

Yahoo | June 11, 2020

Sutro Biopharma to Present New Preclinical Data on its STRO-002 Antibody-Drug Conjugate at the Upcoming AACR 2020 Virtual Meeting on June 22, 2020

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced that the company will present new preclinical data for its folate receptor alpha targeting antibody-drug conjugate, STRO-002, at the American Association for Cancer Research (AACR) Virtual Annual Meeting II being held June 22-24, 2020.

Yahoo | June 9, 2020

Read More 'STRO' Stories Here

STRO Price Returns

1-mo 26.45%
3-mo 65.51%
6-mo 33.13%
1-year 23.30%
3-year N/A
5-year N/A
YTD 16.91%
2019 21.95%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Continue Researching STRO

Here are a few links from around the web to help you further your research on Sutro Biopharma Inc's stock as an investment opportunity:

Sutro Biopharma Inc (STRO) Stock Price | Nasdaq
Sutro Biopharma Inc (STRO) Stock Quote, History and News - Yahoo Finance
Sutro Biopharma Inc (STRO) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6588 seconds.